-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexicon Pharma Presents Additional Clinical Data And Program Updates From Phase 2 Pilavapadin Program At 19th Annual Pain Therapeutics Summit

Benzinga·10/14/2025 12:02:14
Listen to the news

– Results support advancement of 10 mg dose into Phase 3 development –

– End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing –

THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 pilavapadin program at the 19th Annual Pain Therapeutics Summit.

These data follow the topline results from the Phase 2b PROGRESS study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) announced in March of 2025, which identified 10 mg once daily as the most clinically meaningful and appropriate dose to advance into Phase 3 development.